CytomX Therapeutics, Inc. (CTMX) has a consensus analyst rating of Buy, based on 21 analysts covering the stock. Of those, 17 recommend buying, 4 recommend holding, and 0 recommend selling.
The analyst consensus price target for CTMX is $11.60, representing a +155.5% upside from the current price of $4.54. Price targets range from a low of $10.00 to a high of $16.00.
